{
  "consolidation_metadata": {
    "timestamp": "2025-09-10T11:33:17.422101",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "total_consolidated_picos": 25,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE",
        "EN",
        "FR",
        "DK",
        "ES",
        "PT",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
        "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
        "Treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma"
      ],
      "Original_Comparator_Variants": [
        "sorafenib",
        "Sorafenib"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN",
        "ES",
        "FR",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "patients with unresectable hepatocellular carcinoma",
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib",
        "Lenvima (lenvatinib)",
        "leninivat"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "SE",
        "ES",
        "FR"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced or non-resettable HCC",
        "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
        "patients with unresectable hepatocellular carcinoma",
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)"
      ],
      "Original_Comparator_Variants": [
        "Tecentriq (atezolizumab) plus bevacizumab",
        "Tecentriq plus bevacizumab",
        "atezolizumab plus bevacizumab",
        "atezolizumab and bevacizumab",
        "atezolizumab with bevacizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1, when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab plus durvalumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate"
      ],
      "Original_Comparator_Variants": [
        "tremelimumab-durvalumab combination"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1, who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab"
      ],
      "Original_Comparator_Variants": [
        "sorafenib"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (BCLC stage B or C), who have not received prior systemic therapy, with Child-Pugh A liver function and ECOG performance status 0 or 1, who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) following progression on first-line tyrosine kinase inhibitor (TKI) therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "patients who are well tolerant of sorafenib"
      ],
      "Original_Comparator_Variants": [
        "regorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) following progression on first-line tyrosine kinase inhibitor (TKI) therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "cabozantinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) following progression on first-line tyrosine kinase inhibitor (TKI) therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE",
        "FR",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations after sorafenib",
        "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml"
      ],
      "Original_Comparator_Variants": [
        "ramucirumab",
        "ramucyrumab"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) in the second line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) in the second line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line"
      ],
      "Original_Comparator_Variants": [
        "sorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) in the second line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line"
      ],
      "Original_Comparator_Variants": [
        "regorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) in the second line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line"
      ],
      "Original_Comparator_Variants": [
        "cabozantinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) in the second line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line"
      ],
      "Original_Comparator_Variants": [
        "ramucirumab"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "sorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma (HCC) who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "leninivat"
      ]
    },
    {
      "Population": "Patients with advanced hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab plus ipilimumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced hepatocellular carcinoma previously treated with sorafenib"
      ],
      "Original_Comparator_Variants": [
        "nivolumab plus ipilimumab"
      ]
    },
    {
      "Population": "Patients with advanced HCC having a non-viral etiology",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with HCC having a non viral etiology"
      ],
      "Original_Comparator_Variants": [
        "Tecentriq plus bevacizumab"
      ]
    },
    {
      "Population": "Patients with advanced hepatocellular carcinoma in whom intentionally curative treatment or (continuation of) locoregional or local palliative treatment is not possible or is considered not to be medically appropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with (not locally treatable) HCC"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab with bevacizumab"
      ]
    },
    {
      "Population": "Cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis"
      ],
      "Original_Comparator_Variants": [
        "TACE"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial chemoembolization",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "arterial chemoembolization"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive iodine-131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "radioactive Iodine 131 treatment"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "systemic chemotherapy (doxorubicin or cisplatin)"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "hormonal therapy with tamoxifen"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "subcutaneous octreotide therapy",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "subcutaneous octreotide therapy"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "selective internal radiation therapy with yttrium-90 resin microspheres",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable hepatocellular carcinoma"
      ],
      "Original_Comparator_Variants": [
        "selective internal radiation therapy with yttrium-90 resin microspheres"
      ]
    }
  ]
}